Abstract
One approach to improving the results of antibody treatment of posttransplant and other lymphomas is to alter the geometry of the antibody molecule so as to enhance its cytotoxicity. When antibody alights on a cell, cytotoxicity can be exerted by initiation of apoptotic signals at the cell surface, and by recruitment of effectors to specific sites on the antibody Fc region. Other routes to cytotoxicity have been described but their generality is debatable. The effectors consist of complement, and a series of potentially cytotoxic cells (macrophages, NK cells, neutrophils and others) bearing Fc-receptors (FcR). Recent evidence suggests that the FcR-bearing cells are the more important in dealing with antibody-coated autologous cells, including tumor cells. If the antibody happens to be of the host IgG class then its Fc region (Fcγ) will contain a site for attachment of a non-cytotoxic FcR known as FcRB (the Brambell receptor): it is this receptor, present on endothelial cells, which recycles the molecule intact if it happens to be endocytosed and thus prolongs its metabolic life. Replacement of the mouse Fcγ by human Fcγ is expected to have three beneficial effects: better recruitment of human effector cells, better persistence of the antibody in extracellular fluid, and removal of a major source of immunogenic epitopes. Chemical manipulations of Fab’γ and Fey modules, linking them in different geometries via their hinge regions, offers constructs with further enhancements of cytotoxicity These include Fab2Fc2, in which the presence of dual Fc regions enhances recruitment of both complement and cellular effectors; and bispecific antibody of the same modular formula in which one of the Fab arms is specific for tumor while the other is specific for, and recruits powerfully, a cellular effector.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Maloney DG, Grillolopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R (1997) IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195
Glotz D, Antoine C, Garnier JL, Anderson VA, Leong WS, Worth AT, Stevenson GT (1998) Preliminary observations on the treatment of post-transplant lymphomas by multi-Fc chimeric antibodies. Tumor Targeting 3:46–54
French RR, Chan HT, Tutt AL, Glennie MJ (1999) CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-ceU help. Nature Med 5:548–553
Schroff RW, Farrell MM, Klein RA, Stevenson HC, Warner NL (1985) Induction and enhancement by monocytes of antibody-induced modulation of a variety of lymphoid cell surface antigens. Blood 66:620–626
Shan D, Ledbetter JA, Press OW (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644–1652
Ravetch JV, Clynes RA (1998) Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol 16:421–432
Clynes RA, Towere TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Med 6:443–446.
Sondermann P, Huber R, Oosthuizen V, Jacob U (2000) The 3.2-Å crystal structure of the human IgGl Fc fragment-FcyRIII complex. Nature 406:267–273
West AP, Bjorkman PJ (2000) Crystal structure and immunoglobulin G binding properties of the human major histocompatibility comp lex-related Fc receptor. Biochemistry 39:9698–9708
Tao MH, Smith RI, Morrison SL (1993) Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med 178:661–667
lunghans RP, Anderson CL (1996) The protection receptor for IgG catabolism is the β2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93:5512–5516
Stevenson GT (1993) Immunotherapy of tumours. In: Lachmann PJ Peters DK, Rosen FS, Walport MJ (eds) Clinical aspects of immunology. Blackwell Scientific, Oxford, pp 1799–1830
Glennie MJ, Stevenson GT (1982) Univalent antibodies kill tumour cells in vitro and in vivo. Nature 295:712–714
Stevenson GT (1997) Chemical engineering at the antibody hinge. Chem Immunol 65:57–72
Stevenson GT, Anderson VA, Kan KS, Worth AT (1997) Conjugation of human Fcγ in closed-hinge or open-hinge configuration to Fab’y and analogous ligands. J Immunol 158:2242–2250
Kan KS, Anderson VA, Leong WS, Smith AM, Worth AT, Stevenson GT (2001) Thioether-bonded constructs of Fab’y and Fey modules utilizing differential reduction of interchain disulfide bonds. J Immunol 166:1320–1326
Karpovsky B, Titus JA, Stephany DA, Segal DM (1984) Production of targetspecific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fcy receptor antibodies. Exp Med 160:1686–1701
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Stevenson, G.T., Anderson, V.A., Leong, W.S. (2002). Engineered Antibody for Treating Lymphoma. In: Oertel, S.H., Riess, H. (eds) Immunosurveillance, Immunodeficiencies and Lymphoproliferations. Recent Results in Cancer Research, vol 159. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56352-2_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-56352-2_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62676-0
Online ISBN: 978-3-642-56352-2
eBook Packages: Springer Book Archive